Search
for
Sort by
Research 31–60 of 200
- Efluvio anágeno. Hallazgos tricoscópicos
- Use of chemotherapy during human pregnancy
- Dermatological adverse events with taxane chemotherapy
- Protection Against Chemotherapy-Induced Alopecia
- Drug Reactions Affecting Hair: Diagnosis
- Adverse effects of common medications on male fertility
- Anagen effluvium
- Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Permanent Alopecia After Systemic Chemotherapy: A Clinicopathological Study of 10 Cases
- Weekly docetaxel in minimally pretreated cancer patients: A dose-escalation study focused on feasibility and cumulative toxicity of long-term administration
- Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)
- Malignancy and Cancer Treatment-Related Hair and Nail Changes
- Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis
- Pathogenesis and treatment options for chemotherapy‐induced alopecia: a systematic review
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- MicroRNA in skin diseases
- Alopecia in Association with Malignancy: A Review
- The metabolic syndrome- associated small G protein ARL15 plays a role in adipocyte differentiation and adiponectin secretion
- INTERFERONS IN DERMATOLOGY
- The Influence of Various Parameters on the Success of Sensor-Controlled Scalp Cooling in Preventing Chemotherapy-Induced Alopecia
- An Update on Drug-Induced Pigmentation
- Adverse cutaneous reactions to chemotherapeutic agents and cytokine therapy
- Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood
- Radiation- and Chemotherapy-Induced Permanent Alopecia: Case Series
- Limited stage small cell lung cancer
- Clinical Development of Topoisomerase-Interactive Drugs
- Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John’s wort skin oil
- Multiple minute digitate hyperkeratosis
- Rituximab for Bone Lymphoma